Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Belizatinib||TSR-011||ALK Inhibitor 22 Trk Receptor Inhibitor (Pan) 23||Belizatinib (TSR-011) binds to ALK and TRK kinases and inhibits downstream signaling, which may result in decreased proliferation of ALK/TRK expressing tumor cells (PMID: 26753004).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK rearrange||lung non-small cell carcinoma||predicted - sensitive||Belizatinib||Phase I||Actionable||In a Phase I clinical trial, Belizatinib (TSR-011) treatment resulted in a partial response in 60% (3/5) of non-small cell lung cancer patients with an ALK rearrangement (J Clin Oncol 32, 2014 (suppl; abstr e19005)).||detail...|
|ALK rearrange||Advanced Solid Tumor||sensitive||Belizatinib||Phase Ib/II||Actionable||In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK-rearranged advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at a lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)).||detail...|
|EML4 - ALK ALK F1174L ALK G1269A||lung adenocarcinoma||predicted - resistant||Belizatinib||Case Reports/Case Series||Actionable||In a clinical case study, ALK F1174L and ALK G1269A were identified as newly acquired mutations in the pleural effusion from a patient with lung adenocarcinoma harboring an acquired EML4-ALK after his disease progressed on Belizatinib (TSR-011) treatment (PMID: 28434515).||28434515|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02048488||Phase Ib/II||Belizatinib||A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas||Completed|